<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03510416</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-IR-2018</org_study_id>
    <nct_id>NCT03510416</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma</brief_title>
  <official_title>Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma
      Refractory to Transcatheter Arterial Chemoembolization .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aptinib combined with TACE can be generated through embolization and angiogenesis by the dual
      target of vascular suppression.Efficacy and safety of apatinib combined with TACE in patients
      with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time To Progression</measure>
    <time_frame>From the date of first procedure of apatinib combined with TACE until the time when the disease progresses, assessed up to 14 months</time_frame>
    <description>Time to progression is defined as stable with treatment of apatinib combined with TACE after enrollment until lesions are defined as disease progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From the date of randomization until the date of death from any cause, assessed up to 14 months</time_frame>
    <description>From the date of randomization until the date of death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization</condition>
  <arm_group>
    <arm_group_label>apatinib combined with TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib is administered after TACE 4-7 days, and TACE treatment is performed after discontinuation of apatinib for 4 days.Every 28 days is a cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>apatinib is a kind of Inhibitor of VEGFR-2</description>
    <arm_group_label>apatinib combined with TACE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>TACE</intervention_name>
    <description>Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE.</description>
    <arm_group_label>apatinib combined with TACE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-70 years old;Estimated survival time≥12 weeks

          -  Histologicaly and cytologicaly diagnosed as Hepatocellular carcinoma of the liver (
             HCC ) and with At least one imaging examination of measurable lesions (RECIST), CT or
             MR scan Long diameter of tumor ≥ 10 mm.Target lesion without Local treatment

          -  Child-pugh liver function Rating: A level, B level

          -  BCLC Staging as B / C period

          -  ECOG 0-1

          -  Have progressed after at least twice TACE

          -  The main organ function is normal, and meet the following standards:(1)The standard of
             blood routine examination should be consistent: HB≥90 g/L, ANC≥1.5×10^9/L,
             PLT≥60×10^9/L; (2)Biochemical tests should meet the following criteria: ALB ≥29
             g/L；TBIL&lt;2'ULN, ALT and AST&lt;5'ULN,Cr ≤ 1.5*ULN

          -  Fertile woman must perform a pregnancy test (serum or urine) 7 days before screened,
             or voluntarily adopt proper methods of contraception during the observation period and
             8 week after the last given apatinib. For man, surgical sterilization should be
             performed, or voluntarily adopt proper methods of contraception during the observation
             period and 8 week after the last given apatinib

          -  Patients voluntarily entered the study and signed informed consent form (ICF).

        Exclusion Criteria:

          -  Received Any local treatment other than TACE (including but not limited to surgery,
             radiotherapy, hepatic arterial embolization, hepatic arterial infusion, radiofrequency
             ablation, cryoablation, or percutaneous ethanol injection) within four weeks before
             randomization

          -  Participated in other cancer drug clinical trials within four weeks before
             randomization

          -  hepatobiliary cell carcinoma and mixed cell carcinoma are known; previous ( 5 year) or
             at the same time suffering from other incurable malignancies, except for the cured
             basal cell carcinoma of the skin and cervical carcinoma in situ

          -  have received or Prepared for liver transplantation

          -  A serous cavity effusion (including hydrothorax, ascites, pericardial effusion) with
             local symptoms requiring local treatment; or Child-Pugh&gt;2；

          -  Patients with uncontrol hypertension (systolic blood pressure ≥ 140 mmHg or diastolic
             blood pressure ≥ 90 mmHg, despite optimal drug therapy)

          -  Suffering from coronary heart disease, arrhythmia or grade II (including QTc
             prolongation &gt; 450 ms male, female, 470 MS) and Cardiac insufficiency

          -  According to NYHA standard, III ~ IV cardiac insufficiency, or heart colour to exceed
             revealed left ventricular ejection fraction (LVEF) &lt; 50%

          -  There are several factors that affect oral medicine,such as unable to swallow, chronic
             diarrhea and intestinal obstruction

          -  Before randomization within 6 months had significant bleeding clinical significance or
             definite bleeding tendency, such as gastrointestinal bleeding, bleeding gastric ulcer,
             baseline fecal occult blood and above, or suffering from vasculitis

          -  History of abdominal fistula, gastrointestinal perforation or abdominal abscess within
             28 days before randomization

          -  Abnormal coagulation (INR&gt;1.5 or PT&gt;ULN+4, or APTT&gt;1.5 ULN), bleeding tendency or
             receiving coagulation therapy

          -  Central nervous system with symptoms of metastasis

          -  there is typical interstitial pneumonia or pulmonary fibrosis

          -  Patients with a history of psychiatric drug abuse and can not be prevented or have
             mental disorders

          -  before participating in the study 7 days use strong-effect in CYP3A4 inhibitor
             therapy, or prior to participating in the study 12 days use the strong-effect in
             CYP3A4 inducer Therapy

          -  pregnant or lactating women who are not willing or unable to take effective
             contraceptive measures

          -  A history of mental illness, or psychotropic substance abuse

          -  Patients with allergies to research drugs

          -  Other patients who were considered unsuitable for inclusion by physicians.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhiping Yan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Interventional Radiology, Zhongshan Hospital, Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zhiping Yan, MD</last_name>
    <phone>13681971205</phone>
    <email>yan.zhiping@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>wei Zhang, MD</last_name>
    <phone>13917737593</phone>
    <email>zhang.wei6@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2018</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>apatinib，TACE， hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

